Caspian Therapeutics and Kura Oncology detail Phase‑1 plan for oral menin inhibitor KO‑7246
Caspian Therapeutics and Kura Oncology announced the development strategy for KO‑7246, an oral menin inhibitor aimed at restoring insulin‑producing beta cells in diabetes. Preclinical studies in mice, rats and human islet tissue showed expanded beta‑cell mass, higher insulin levels and sustained glucose control after treatment stopped. The companies said they will begin IND‑enabling work and target a Phase 1 proof‑of‑concept trial to evaluate safety and endogenous insulin production. The webcast to discuss the plan was scheduled for 4:30 p.m. Eastern and 1:30 p.m. Pacific time on Oct 13, 2026.
Why it matters
The Phase 1 trial will determine whether KO‑7246 can safely increase insulin production in patients, a result that could create a disease‑modifying therapy for diabetes. Successful data could drive further funding and increase Kura’s valuation, as it retains roughly 50 % ownership of Caspian.
Key facts
- 1Caspian and Kura will outline the KO‑7246 development strategy in a webcast on Oct 13, 2026. stocktitan.net
- 2KO‑7246 is a selective oral menin inhibitor being developed for diabetes and other chronic metabolic diseases. stocktitan.net
- 3Preclinical mouse studies showed KO‑7246 increased insulin levels and expanded beta‑cell mass, with durable glucose control when combined with semaglutide. stocktitan.net
- 4In a rat model of severe insulin deficiency, treated animals maintained normal blood sugar and elevated stimulated C‑peptide for one month after stopping the drug. stocktitan.net
- 5KO‑7246 stimulated beta‑cell proliferation in human islet microtissue samples without affecting other cell types. stocktitan.net
- 6Kura contributed KO‑7246 IP and retains approximately half ownership of Caspian, which was launched in September 2026 with $50 million of financing. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.